Biotech News by Date
Yahoo! Groups : Biotechnology News
Archives
05/01/2005 - 05/31/2005
06/01/2005 - 06/30/2005
07/01/2005 - 07/31/2005
08/01/2005 - 08/31/2005
09/01/2005 - 09/30/2005
10/01/2005 - 10/31/2005
11/01/2005 - 11/30/2005
More blogs about biotech
news
arizona
biotechnology
genomics
Bioinformatics
Nanotechnology.
Biotech News <<< Mailing List
Biotechnology News <<< Discussion Forums
FRC Statement on Frist Support for Embryonic Stem Cell Research
FRC Statement on Frist Support for Embryonic Stem Cell Research
Friday July 29, 12:27 pm ET
WASHINGTON, July 29 -- Today, Senate Majority Leader Bill Frist (R-TN) announced on the floor of the Senate his support for public funding of additional human embryo destruction for human embryonic stem cell research and an expansion of President Bush's policy regarding funding of such research. Family Research Council President Tony Perkins released the following statement:
"Senator Frist's announcement is very disappointing but not a surprise. It is reminiscent of the speech he gave to the 2004 Republican platform committee, where he squelched open debate on the ethics of embryonic stem cell research, as well as a 2001 Senate hearing testimony where he advocated production of hundreds of human embryonic stem cell lines, which would have required destruction of thousands of human embryos.
"As a heart surgeon who knows that adult stem cells are already making huge progress in treating heart disease in humans, it is unfortunate that Sen. Frist would capitulate to the biotech industry. Under the current policy, 22 human embryonic stem cell lines, and over 3500 vials of such cells, are available for research; 39 more lines wait in the freezer for researchers to use them, and there is no cap on the federal money available for this research. Yet after 24 years of work with mouse and human embryonic stem cells, this 'promising' research has delivered not a single treatment for human patients and sparse results in mice. Thankfully the White House has forcefully promised to hold the ethical line and veto any legislation that would expand the President's current policy.
"Meanwhile, thousands of patients are better TODAY after umbilical cord blood and adult stem cell treatments for at least 65 conditions, including over 200 heart patients, results of which heart surgeon Dr. Frist should take notice. The progress of adult stem cell research, including evidence that they, too, are pluripotent, is causing many scientists to rethink their support for embryonic stem cell research. Senator Frist, please support good science, good ethics, and good public policy."
--------------------------------------------------------------------------------
Source: Family Research Council
Biotechnology News at Arizona Biotech Arizona Biotech News - BioTech News at Arizona Biotech - Arizona Biotechnology News
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
[ biotech news ] Genetic Engineering News Reports on Stem Cell Fact and Fiction
Genetic Engineering News Reports on Stem Cell Fact and Fiction
NEW ROCHELLE, N.Y.
July 13, 2005--Scientists around the world are employing a variety
of methods to translate human stem cell research into bona fide
therapies for a host of diseases, reports Genetic Engineering News
(GEN) (www.genengnews.com). However, technical and, particularly in
the U.S., societal questions need to be addressed before stem cell
technology can reach its full potential, according to the July issue
of GEN.
"The bottom line is that stem cell research is young," says John
Sterling, Editor-in-Chief of GEN. "But this fact is often overlooked
as a result of some of the hype over stem cells and because of the
intense controversy the topic has engendered in a number of
religious and political circles."
While the U.S. is engaged in a debate over reinstituting the use of
federal funds to support new embryonic stem cell research,
scientific matters remain to be resolved. These include gaining more
knowledge about the stages of cellular differentiation, the numbers
of stem cells needed for therapeutic applications and the types of
delivery systems that will be required, the length of time that stem
cells can function in animal models, and the optimal combination of
growth factors and cell culture conditions for stem cells.
Some companies, such as Aastrom Biosciences (NASDAQ:ASTM) and
MultiCell Technologies (NASDAQ:MCET), are working with adult stem
cells. For example, in a clinical trial involving long bone non-
union fractures, all patients treated with Aastrom's tissue repair
cells exhibited both clinical and functional healing and, at six
months, five of the six showed bone regeneration at the fracture
site. MultiCell Technologies won a patent this spring that
incorporates hepatocytes with stem cells that can differentiate into
mature, functioning, hepatocyte or bile duct cells that eventually
may treat degenerative liver diseases or inherited functional
deficiencies in the liver.
Cytori Therapeutics (Frankfurt:XMP), formerly MacroPore Biosurgery,
sees a future in fat, which is an excellent source of stem cells.
The company, which works with large animals at several academic
centers in the U.S. and abroad and, in collaboration with UCLA, with
small animals, has published data showing the benefits of fat-
derived stem cells.
Geron Corp. (NYSE:GERN) demonstrated proof of concept injecting
oligodendrocytes and dopaminergic neurons derived from human
embryonic stem cells directly into injured spinal cords in rats and
found motor improvement. An early study to repopulate heart tissue
was also successful.
Stem cell research at ReNeuron and BioE is also covered in the GEN
article.
Genetic Engineering News is published 21 times a year by Mary Ann
Liebert, Inc.
Arizona Biotech
Biotech News
Biotechnology Forum
Arizona Entrepreneurs
Arizona High Tech
Biotech News
Biotech News
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Genetically Modified Organisms (GMOs) Workshop
Genetically Modified Organisms (GMOs) Workshop
General News of Thursday, 28 July 2005
Workshop on organisms opens
Accra, July 28, GNA - A workshop on Genetically Modified Organisms (GMOs) on Thursday opened in Accra to discuss and debate the benefits and risks in applying the GMOs in various key sectors of Ghana's economy.
Genetically Modified Organisms are genetic engineering tools for producing new varieties and new products in agriculture, health and industry.
The Science and Technology Policy Research Institute (STEPRI) of the Centre for Scientific and Industrial Research (CSIR) is hosting the workshop being attended by stakeholders who would exchange ideas and provide inputs to policy formulation on the application of GMOs in Ghana.
Participants would also address issues of Ghana's effort to take full advantage of genetic engineering, issues of risk management, capacity building and investment.
Professor Emmanuel Owusu Bennoah, Director General, CSIR, said despite the risks involved with any scientific technology, Ghana could take advantage of the GMOs in her agriculture productions to enable her to become food sufficient.
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Genetic Engineering of Flowers
Genetic Engineering of Flowers
By Jacquie Kangas
July 28, 2005
My childhood memories are filled with the fragrance of flowers.
American Chronicle: Genetic Engineering of Flowers
How have we allowed genetic engineering of flowers to progress so far that young adults today are not even aware that various flowers once had beautiful fragrances? I am told flowers are being altered to increase their size, colour and bloom time. I haven't noticed that cut flowers last any longer, but some varieties do, indeed, come in stunning new colours, but at what expense?
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
[ biotech news ] North Carolina Biotechnology Center
North Carolina Biotechnology Center
Triad Group to Release 21 Ideas for Boosting Biotechnology
Lt. Gov. Beverly Perdue to speak at Triad BioNight celebration
tonight
GREENSBORO, N.C., July 14 -- The Advisory Committee for
Biotechnology in the Piedmont Triad will formally release 21
strategic recommendations for strengthening the industry during the
Triad BioNight reception and awards banquet tonight at the O. Henry
Hotel.
The advisory committee, a group of more than two dozen academic and
industry leaders working with the North Carolina Biotechnology
Center, drafted the recommendations to work in tandem with Gov. Mike
Easley's plan New Jobs Across North Carolina: A Strategic Plan for
Growing the Economy Statewide Through Biotechnology.
"A statewide plan for biotechnology is in effect, and now a strong
plan has taken shape that is tailored to the Piedmont Triad region's
needs and effort," said Russ Read, vice chair of the advisory
committee and executive director for the National Center for the
Biotechnology Workforce at Forsyth Technical Community College. "As
a part of the larger concerted effort, this is a most significant
accomplishment for the region and for the continuing effort of
biotechnology economic promotion for all of North Carolina."
The advisory committee's 21 recommendations call for:
- Creating a regional directory of goods manufactured by local
biotechnology companies;
- Building a database of available wet lab space;
- Forming a legislative team to monitor the Triad's
biotechnology
priorities;
- Collecting economic and academic data from primary and
secondary data
sources;
- Hosting a reception dinner to showcase the Triad's
biotechnology
community;
- Partnering with the Council of Entrepreneurial Development to
host
Biotech 2006;
- Developing national and regional public relations and
advertising
campaigns extolling the virtues of the Triad's biotechnology
community;
- Marketing agricultural biotechnology;
- Creating intellectual exchange groups based on scientific
topics;
- Operating databases of university research and intellectual
property
assets;
- Providing more interaction between the Triad's universities
and
industry members;
- Developing innovative training and career programs;
- Creating a Translational Research Center for the central
nervous system
and behavioral sciences;
- Promoting community college programs and develop new ones
based on
industry feedback;
- Determining recruiting needs and the alliances needed to
bring renowned
researchers to the Triad;
- Creating financial packages to support recruitment efforts;
- Forming a welcoming committee for new clients;
- Providing affordable, short-term office/lab space by creating
a "wet-
lab hotel";
- Creating low-cost office space for foreign countries to place
a
regional liaison;
- Forming a team with local partners to recruit contract
manufacturing
companies;
- Attracting entrepreneurs to develop businesses around the
region's
Centers of Excellence like the Institute for Regenerative
Medicine.
The recommendations reflect about 18 months of work for the advisory
committee.
"Through efforts such as those of the Advisory Committee for
Biotechnology in the Piedmont Triad, we are building a community to
support biotechnology that has few equals nationally or
internationally," said Committee Chair Dr. Rosemary Wander,
associate provost for research at the University of North Carolina
at Greensboro.
The next step, said Gwyn Riddick, director of the Piedmont Triad
Office of the Biotechnology Center, is for six project teams
appointed by the advisory committee to begin implementing the 21
recommendations in concert with partner organizations in the
Piedmont Triad.
One of the recommendations will come to fruition tonight when the
Biotechnology Center and 29 other sponsors host the Triad BioNight
celebration, at the O. Henry Hotel, 624 Green Valley Road, in
Greensboro, starting at 6 p.m.
The event will feature a keynote address by Lt. Gov. Beverly Perdue
on biotechnology and the new economy and a networking reception and
awards banquet for the Piedmont Triad's biotechnology community.
Other speakers will include Don deBethizy, CEO of Targacept;
biotechnology entrepreneur Max Wallace, chairman of the Innovation
Foundation and president of The Arbor Group; and Leslie Alexandre,
president and CEO of the Biotechnology Center.
In addition, Gayle Anderson, president of the Winston-Salem Chamber
of Commerce, will give an update on the Triad's biotechnology
assessment and index project.
Five awards will be given to honor the work of key leaders in the
Piedmont Triad's biotechnology community. The awards, and their
recipients, are:
- Research and Development Excellence: Anthony Atala, M.D.,
director,
Institute for Regenerative Medicine, and chair, Department of
Urology,
Wake Forest University Health Sciences
- Entrepreneurial Excellence: Roland H. Johnson, president &
CEO,
Piedmont Pharmaceuticals
- Academic Development Excellence: Gary M. Green, Ed.D.,
president, and
Lucas Shallua, D.Sc., biotechnology program coordinator,
Forsyth
Technical Community College
- Piedmont Biotechnology Community Leadership Excellence: Gwyn
Riddick,
director, Piedmont Triad Office, North Carolina Biotechnology
Center
- Biotechnology Service and Support Excellence: Bill Dean,
president,
!dealliance
The North Carolina Biotechnology Center, headquartered in Research
Triangle Park with satellite offices in Winston-Salem and Asheville,
is a state-supported, non-profit corporation. Its mission is to
provide long-term economic and societal benefits to North Carolina
by supporting biotechnology research, business and education
statewide.
---------------------------------------------------------------------
-----------
Source: North Carolina Biotechnology Center
Biotech in Arizona
Biotechnology News
Entrepreneurs in Arizona
High Tech in Arizona
Biotechnology Forum
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Howrey LLP - United Kingdom - Cambridge Antibody Technology V Abbott Biotechnology Limited (25/07/2005) from Mondaq
Howrey LLP - United Kingdom - Cambridge Antibody Technology V Abbott Biotechnology Limited (25/07/2005) from Mondaq
United Kingdom: Cambridge Antibody Technology V Abbott Biotechnology Limited
Free Weekly Newsletters
Would you like to be kept informed about similar articles? >Signup<
Further information
Give Firm your Feedback
Sign up for a free News Alert
Information contributed by Howrey LLP
View all Articles by this Firm
View summary of all information contributed
View Firm's Website
General links
Email a colleague with a synopsis and link to this article
Printer-friendly version of this page
Become a contributor
Legal Jobs
View Other Articles Classified By:
Intellectual Property
Pharmaceutical, Healthcare & Life Sciences
Biotechnology, Life Sciences & Healthcare
Licensing & Syndication
Patent
Trade Secrets
Arbitration & Dispute Resolution
Commercial
Healthcare/ Medical
Life Sciences & Biotechnology
Patents
25 July 2005
Article by Calum Smyth
In one of the year’s most valuable contract claims to come before the UK Patents Court, the CAT v Abbott dispute demonstrates the importance of properly understanding both the extent of existing IP rights and the nature of the protected technology, when drafting commercial agreements in technically complex fields.
Under two collaboration agreements (the "Agreements") Abbott was licensed to use CAT's patented technology in order to develop an antibody to a protein known as TNFa - a protein thought to play a large part in rheumatoid arthritis. The case concerned a dispute over the amount of royalties payable in relation to Abbott's sales of HUMIRA, a blockbuster biologic rheumatoid arthritis drug that utilises the TNFa antibody....
Biotech in Arizona
Biotechnology News
Entrepreneurs in Arizona
High Tech in Arizona
Biotechnology Forum
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
[ biotech news ] GOVERNMENT SUPPORTS BIO-TECHNOLOGY DEVELOPMENT
GOVERNMENT SUPPORTS BIO-TECHNOLOGY DEVELOPMENT
---------------------------------------------------------------------
-----------
17:51 IST
Lok Sabha
The Department of Biotechnology provides grant-in-aid support for
research & development, and capacity building in the area of
biotechnology to universities, research institutes and not-for-
profit organizations across the country. In addition grant-in-aid
is also provided for creation of Centers of Excellence in emerging
areas. During the last 5 years more than 2000 R&D Projects have
been supported; 74 universities have been supported for post-
graduate biotechnology programmes, 60 universities and research
institutes have been provided support for bioinformatics network
centers. In addition 57 biotechnology infrastructure facilities
have been established across the country for cutting edge basic
research and process and product development.
To promote excellence in biotechnology it is proposed to
establish Centers of Excellence in the areas of :
Ø Transnational research in public health
Ø Stem Cell
Ø Marine biotechnology
Ø Animal biotechnology
Ø Nutritional genomics and food biotechnology
Ø Herbal Medicine
Ø Molecular medicine
Ø Bio-materials and devices and
Ø Bio-informatics
In addition centers would also be supported in other frontier
emerging areas of Biotechnology.
This information was given by Shri Kapil Sibbal,
Minister of State, Science and Technology and Ocean Development in
Lok Sabha today.
Biotech in Arizona
Biotechnology News
Entrepreneurs in Arizona
High Tech in Arizona
Biotechnology Forum
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
[ biotech news ] DuPont Announces New Biotechnology Advisory Panel Member
DuPont Announces New Biotechnology Advisory Panel Member
Thursday July 28, 11:45 am ET
WILMINGTON, Del., July 28 -- DuPont today announced the addition of
Mr. Chebet Maikut to its external Biotechnology Advisory Panel. Mr.
Maikut is the president of the Uganda National Farmers Federation
(UNFFE), one of the largest farmer organizations in Uganda. He joins
the ranks of seven other distinguished panel members who bring
important and diverse viewpoints to the broad area of biotechnology
and its application in agriculture, food and bio-based materials.
"Chebet Maikut's knowledge of African agriculture will provide
valuable insight into biotechnology policy and acceptance from the
perspective of a developing country and market," said DuPont
Chairman and CEO Charles O. Holliday, Jr. "He brings a strong voice
that represents both African opinions on biotechnology as well as
prospective customer segments in this emerging market."
As a farmer in the Kapchorwa District, Uganda, Maikut is no stranger
to the challenges facing African growers. He has dedicated his
career to empowering others to create a better quality of life
through the development of a sustainable African agricultural
industry. In addition to his role at the UNFFE, Maikut holds several
other leadership positions, including vice president, Eastern Africa
Farmers Federation (EAFF) and member of the Interim Panel of Eminent
Experts to the Global Crop Diversity Trust. He is also an active
participant of the CGIAR Sub-Saharan Challenge Program.
Formerly, Maikut was chairman of the International Federation of
Agricultural Producers' Committee on Science and Technology; a
District Councilor, Constituent Assembly (CAD) and a member of
Parliament (MP) in the National Assembly of Uganda representing
Kween in the Kapchorwa District. Before then, he worked with the
Republic of Uganda Ministry of Agriculture Animal Industry and
Fisheries (MAAIF).
Established in 2000, the DuPont external Biotechnology Advisory
Panel is an independent panel charged with providing counsel to
guide DuPont's actions, help create positions on important issues,
as well as challenge the organization in the development, testing
and commercialization of new products based on biotechnology.
In addition to Maikut, the other panel members include:
-- Dr. Marcelo Carvalho de Andrade, an accomplished advocate of
sustainable community development and environmental
preservation and
restoration. He is the founding chairman of Pro-Natura, the
first
international, nongovernmental organization headquartered in
the
Southern Hemisphere to specialize in sustainable development.
-- Professor Chunming Chen, founding president of the Chinese
Center for
Disease Control and Prevention and currently senior advisor
and
professor of nutrition. Professor Chen is an internationally
recognized expert in nutrition.
-- Dr. Pablo Eyzaguirre, senior scientist for anthropology and
socio-
economics in the Genetic Resources Science and Technology
group of the
International Plant Genetic Resources Institute (IPGRI)
based in Rome.
Dr. Eyzaguirre is a specialist in social and ecological
anthropology,
tropical farming systems, and agrarian institutions.
-- Father Kevin T. FitzGerald, S.J., Ph.D., research associate
professor
in the Department of Oncology at Georgetown University
Medical Center.
Father FitzGerald is internationally known and sought after
for his
expertise in human genetic engineering, cloning and stem cell
research.
-- Carol Tucker Foreman, well-known and respected consumer
advocate and a
distinguished fellow and director of the Consumer Federation
of
America's Food Policy Institute. Foreman has had a major
impact on
diet and health in the United States over the last 25 years.
-- Dr. V. Prakash, director of the Central Food Technological
Research
Institute (CFTRI) in Mysore, India. He is internationally
known for
his work in sustainable food and nutrition security. As a
scientist
in the area of biotechnology, Dr. Prakash has won a large
number of
awards and is a member of several international committees.
-- Dr. Sven Thormahlen, vice president of the Research and
Development
Organization of the Danone Group, a world leading company in
the field
of dairy products, biscuits and mineral water. Thormahlen's
experience covers product research, product development,
clinical
studies and quality assurance.
The work of the advisory panel is facilitated by the Keystone
Center, a non-profit organization based in Keystone, Colo., which
includes a regular audit of DuPont's progress in the biotechnology
arena. This public report is available at
http://www2.dupont.com/Biotechnology/en_US/difference/advisory.html .
DuPont is a science company. Founded in 1802, DuPont puts science to
work by creating sustainable solutions essential to a better, safer,
healthier life for people everywhere. Operating in more than 70
countries, DuPont offers a wide range of innovative products and
services for markets including agriculture, nutrition, electronics,
communications, safety and protection, home and construction,
transportation and apparel.
Biotech
Biotech
Entrepreneurs
High Tech
Biotechnology
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
[ biotech news ] Biotechnology Asia 2005 Expects 6,000 Trade Visitors
Biotechnology Asia 2005 Expects 6,000 Trade Visitors
KUALA LUMPUR, July 29 (Bernama) -- Biotechnology Asia 2005
Exhibition and Conference is expected to attract 6,000 trade
delegates, speakers, policy makers, industry professionals and
researchers who will gather to discuss opportunities and challenges
in the fast-booming biotech industry.
Conference organising chairman Dr Abdul Reezal Abdul Latif said last
year's event had received good response with 5,000 trade visitors
from 15 countries.
The exhibition this year will be held at the Putra World Trade
Centre (PWTC) here from August 16 to 18.
At a press conference here today, Abdul Reezal said 45 local and
international companies have confirmed their participation in the
exhibition which would showcase an array of products and services.
The inaugural Biotechnology 2005 Innovation Awards will also be
presented during the event.
http://www.bernama.com.my/bernama/v3/news_business.php?id=147517
Biotech
Biotech
Entrepreneurs
High Tech
Biotechnology
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
5th Annual Biotechnology Educators Conference focused on food safety
North Texas e-News
5th Annual Biotechnology Educators Conference focused on food safety
By Janet K. Gregg, Texas A&M
Jul 24, 2005
"The positive confirmation of a cow in Texas with BSE and occasional incidents involving food contamination are examples of the need for continuing public and professional education on the topic of food safety. The Biotechnology Conference is a unique opportunity to gather all of the information and experts together to achieve that for educators.” – Rebecca Parker, Regional Program Director–ANR, Texas Cooperative Extension
� Who: Texas Cooperative Extension, Texas Agricultural Experiment Station, Texas A&M University, University of Texas Southwestern Medical Center at Dallas, University of Texas at Dallas, Collin County Community College and Region 10 Education Service Center
� What: Topics include: “Science, from Nobel to Neighborhoods”, “Ensuring Consumer Confidence in the Food/Fiber System”, “Biosecurity Issues: Food, Water & Animal Agriculture”, “Cloning Animals”, “Forensic DNA Analysis”, “The National Animal Identification System”, “Beastly Biotechnology” and “The Application of DNA Profiling”.
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
[ biotech news ] Women in Biotechnology Issues Invitation to 4th Annual Boston Breakfast Meeting
Women in Biotechnology Issues Invitation to 4th Annual Boston
Breakfast Meeting Aug. 9, 2005
Exciting Program Planned on Biotech Public Affairs Issues
The Boston Chapter of Women in Biotechnology issued an invitation
today to its 4th Annual Breakfast Meeting, which features three
prominent industry public affairs practitioners exploring the
theme, "Promoting Your Company's Agenda" regarding public affairs
issues. The speakers will reflect on how public affairs
professionals present company and industry positions on products,
reimbursement and legislative issues, and how to raise the money to
afford them. The meeting will be held on August 9, 7:30-9:30 AM at
the D'Arbeloff Suite at Boston's Museum of Science. Continental
breakfast and networking from 7:30-8 AM.
The meeting is sponsored by Thermo Electron Corporation, a worldwide
manufacturer of laboratory, analytical, measurement and control
instruments and software.
Program Speakers Will Explore Public Affairs Issues in Biotech
All three program speakers are respected public affairs
practitioners who will be imparting a wealth of knowledge on
product, reimbursement and legislative issues. The speakers are:
-- Janice Bourque, Senior Vice President, Comerica Incorporated
-- Susan Zagame Reardon, Esq., Director of Federal Affairs, Johnson
& Johnson
-- Janet Trunzo, Executive Vice President for Technology and
Regulatory Affairs, AdvaMed (Advanced Medical Technology
Association)
Meeting Registration Available Online
Register online for Women in Biotechnology's 4th Annual Breakfast
Meeting at www.womeninbiotechnogy.com. For questions, please contact
Kathleen Bernstein at kb@seidlerbernstein.com. On-site registration
will be accepted on a space-available basis, members, $50, non-
members, $80.
About Women in Biotechnology: Women in Biotechnology is a multi-
disciplinary, global coalition of women looking for an informal
setting to exchange ideas. Women in Biotechnology meets periodically
for informational, educational and networking sessions around events
relevant to our field. Women in Biotechnology founders are Kathleen
Bernstein of Seidler Bernstein, Inc.; Lena Chow of City of Paris,
Inc.; and Kathleen Dunn of KFDunn and Associates. In support of the
professional growth of their peers, the founders of Women in
Biotechnology encourage ongoing development of new leaders for the
group. To learn more, visit www.womeninbiotechnology.com.
Biotech
Biotech
Entrepreneurs
High Tech
Biotechnology
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
[ biotech news ] Prana Biotechnology Strengthens Board With Non-Executive Appointment
Prana Biotechnology Strengthens Board With Non-Executive Appointment
Friday July 29, 8:00 am ET
MELBOURNE, Australia, July 29 -- Prana Biotechnology Limited
(Nasdaq: PRAN, ASX: PBT), is pleased to announce the appointment of
Peter Marks as a non-executive director. Mr. Marks brings to Prana
extensive experience in the areas of corporate finance and advice
and venture capital investment, having specialized in capital
raisings (for listed and unlisted companies), underwritings and
initial public offerings in London and Australia.
Mr. Marks currently serves as Executive Chairman of Premier Bionics
Ltd., an investment company focused on investing in later stage
Australian-based research and development projects that demonstrate
strong commercial potential. He has served as an Associate Director
of McIntosh Securities, now Merrill Lynch Australia, as well as held
senior corporate finance positions at Barings Securities Ltd. and
Burdett Buckeridge & Young Ltd. in their Melbourne offices. In his
roles with these various financial institutions, he was responsible
for advising a substantial number of listed and unlisted companies
on issues ranging from corporate and company structure, to
valuations, business strategies, acquisitions and international
opportunities.
In addition, Mr. Marks has served as Head of the Melbourne Companies
Department at the Australian Stock Exchange; been a founding
Director of Momentum Funds Management Pty Ltd, an Australian venture
capital firm; and was employed by KPMG Corporate Finance Ltd
(Australia), where he rose to Director and was responsible for
heading up the equity capital markets group in Melbourne.
Geoffrey Kempler, chairman and CEO of Prana, said, "Peter brings
invaluable and highly relevant financial experience to the Board, as
well as wise counsel. His appointment brings to three the number of
non-executives on the Board. Peter will serve on the Audit
Committee, helping to maintain a high level of corporate compliance."
Mr. Marks holds a Bachelor of Economics, Bachelor of Laws and
Graduate Diploma in Commercial Law from Monash University in
Melbourne, Australia. He completed his MBA at the Scottish School of
Business at the University of Edinburgh.
About Prana Biotechnology Limited
Prana Biotechnology was established to commercialize research into
Alzheimer's disease and other major age-related degenerative
disorders. The company was incorporated in 1997 and listed on the
Australian Stock Exchange in March 2000 and listed on NASDAQ in
September 2002. Researchers at prominent international institutions
including the University of Melbourne and Massachusetts General
Hospital, a teaching hospital of Harvard Medical School, discovered
Prana's technology.
Biotech
Biotech
Entrepreneurs
High Tech
Biotechnology
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotech shares up after Senate Majority Leader Bill Frist supports embryonic stem-cell research
Biotech share prices rise after Senate Majority Leader Bill Frist supports embryonic stem-cell research
Stock Market News and Investment Information | Reuters.com
Biotech shares up after Sen. Frist support
Fri Jul 29, 2005 9:12 AM ET
(Adds Geron, Aastrom, Stemcells)
NEW YORK, July 29 (Reuters) - Shares of three stem-cell research companies gained before the bell on Friday after U.S. Senate Majority Leader Bill Frist threw his support behind legislation to expand embryonic stem-cell research. [ID:nN29421279]
Shares of Geron Corp. (GERN.O: Quote, Profile, Research) were up 4.5 percent to $10.67 on the Inet electronic brokerage network, from a $10.21 close.
Aastrom Biosciences Inc. (ASTM.O: Quote, Profile, Research) rose 5.9 percent to $3.21 on Inet from their $3.03 close.
Stemcells Inc. (STEM.O: Quote, Profile, Research) jumped 10.7 percent to $5.79 on Inet from a close of $5.23. All three stocks trade on Nasdaq.
Health Books
Funny Quotes
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Magazine ranks New York No. 2 for biotechnology - 2005-07-26
Magazine ranks New York No. 2 for biotechnology - 2005-07-26
Magazine ranks New York No. 2 for biotechnology
Richard A. D'Errico
The Business Review
Gov. George Pataki touted the July issue of Business Facilities Magazine, which ranked New York No. 2 in the nation for developing biotechnology.
Recent Company News
» Business Facilities Magazine
Latest News
» Local Filene's to close following Federated/May merger
» Journal Register paying dividends
» Lawyer to address nanomedicine at World Future Symposium
» Daughters of Sarah names new CEO
» Intermagnetics revenue jumps 49 percent
More
» Companies in the News
» People in the News
Business Facilities is a magazine for companies seeking to expand or relocate their companies.
"The State's high ranking in this important industry magazine is yet another sign that our unprecedented efforts to promote high-tech, biotech and small tech research and economic development is returning major dividends," Pataki said. "The high technology we're creating today is helping to create the new jobs and economic growth of the future all across New York state."
Phoenix Arizona
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
[ biotech news ] Biotech CEOs Seek SBA Fix to Continue Their Medical Research
281 Biotech CEOs Seek SBA Fix to Continue Their Medical Research
WASHINGTON, July 26, 2005
To demonstrate its support of H.R.2943 and S.1263, the "Save
America's Biotechnology Innovative Research (SABIR) Act," the
Biotechnology Industry Organization (BIO) today submitted a letter
to Congress endorsed by 281 biotechnology CEOs and senior executives
who are asking that this legislation be passed.
The legislation, introduced in the House by Sam Graves (R-Mo.) and
in the Senate by Kit Bond (R-Mo.), corrects the Small Business
Administration's (SBA) new interpretation of eligibility standards
related to Small Business Innovation Research (SBIR) grants.
The Rural Enterprises, Agriculture and Technology Subcommittee of
the House Small Business Committee is holding a hearing on the issue
at 2 p.m. Wednesday, July 27 in Room 2360 of the Rayburn House
Office Building. Douglas A. Doerfler, president and CEO of MaxCyte
Inc., of Gaithersburg, Md., will testify on behalf of BIO.
The SBA's action has forced many biotechnology companies to stop or
curtail research into therapies for many diseases, including HIV,
lupus, diabetes, leukemia, Alzheimer's and West Nile virus.
Presently, companies that are 51 percent owned by a group of venture
capital firms are not eligible for SBIR grants. Most small and
emerging biotechnology companies, which are years away from owning
revenue-generating drugs or biologics, must look to the venture
capital community for investments to fund the very high-cost
preclinical and clinical research.
"Prior to the SBA's new interpretation, many small biotechnology
companies relied on SBIR grants to validate the potential of their
research as they raised critical start-up investment funds," said
Jim Greenwood, BIO's president. "In submitting this letter, endorsed
by 281 CEOs -- many of whom run companies that have been impacted by
the new interpretation -- we urge Congress to support this new
legislation and re-start the flow of funds to innovative
biotechnology companies."
Doerfler and Morrie Ruffin, BIO's executive vice president of
capital formation and business development, discuss the impact of
SBIRs on the biotechnology industry during a BioLive Webcast for BIO
members. An excerpt can be viewed at
members.bio.org/biovideos/biolive_0705s.asx.
BIO represents more than 1,100 biotechnology companies, academic
institutions, state biotechnology centers and related organizations
across the United States and 31 other nations. BIO members are
involved in the research and development of healthcare,
agricultural, industrial and environmental biotechnology products.
http://www.arizonabiotech.com/
Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
Biotech News
http://www.arizonaentrepreneurs.com/
Arizona Entrepreneurs
http://www.azhttp.com/
Arizona High Tech
Biotechnology News Forums
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
[ biotech news ] New Report Examines Biotech Giant Amgen�s Success and Future Direction
New Report Examines Biotech Giant Amgen's Success and Future
Direction
Amgen is the world's largest biotechnology company and the eighth
largest pharmaceutical company worldwide, with revenues reaching $10
billion in 2004. Arrowhead Publishers' new report takes a detailed
look at the company's many successes and its strategy for the
future. (www.arrowheadpublishers.com/Amgen.html)
Minneapolis, MN July 26, 2005 -- Amgen is the world's largest
biotechnology company and the eighth largest pharmaceutical company
worldwide. Revenues have nearly doubled in the last three years,
going from $5.52 billion in 2002 to $10.55 billion in 2004. Yet the
majority of revenue is based on twenty-year old technology. Can
Amgen continue its amazing revenue growth? Or will it fall behind,
lacking the small molecule therapeutics that are the main stay of
modern pharmaceuticals?
Arrowhead Publishers' new report entitled "Amgen: Profile, Patents
and Pipeline" answers these important questions. It provides
detailed analysis and information concerning Amgen's business
activities. This report also includes a thorough accounting of the
company's patents and patent applications.
This report provides an in-depth analysis of Amgen's
Strategic strengths and weaknesses
Current therapeutic products and pipeline of future products
Financial analysis, including R&D productivity
Current patents and patent applications
Alliances, joint ventures and acquisitions
Key personnel
Who should buy this report?
Biotech and pharmaceutical companies of all sizes interested in
understanding Amgen's rapid climb to success and its future
direction
Early stage biotechnology companies interested in understanding
Amgen Ventures strategy for investing its $100 million
Financial analysts looking for an in-depth technical analysis
of Amgen's future revenue sources
Key reasons to purchase this report
Competitive intelligence
Benchmark company performance against the leading biotechnology
company
Understand what is driving Amgen's growth, and what is holding
it back
This 81 page up-to-date report, based on information gathered
through the end of the first quarter 2005, contains five tables on
Amgen's pipeline; a listing of the last three years of granted
patents, analyzed by therapeutic area as well as therapeutic form; a
breakdown of sales for all key products; both U.S. and
International, as well as a list of all patent applications for 2004
through the first quarter of 2005.
http://www.arizonabiotech.com/
Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
Biotech News
http://www.arizonaentrepreneurs.com/
Arizona Entrepreneurs
http://www.azhttp.com/
Arizona High Tech
Biotechnology News Forums
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Gurus Buy Biotech And Software, Trim Health Care - Forbes.com
Gurus Buy Biotech And Software, Trim Health Care - Forbes.com
Guru Picks
Gurus Buy Biotech And Software, Trim Health Care
John Dobosz, 07.26.05, 10:00 AM ET
NEW YORK - The Nasdaq Composite tacked on another 1.06% last week, again leading the gains of the S&P 500 Index (+0.47%) and the Dow Jones Industrial Average (+0.1%). Some of the biggest drivers of the Nasdaq's performance have been in the red-hot sectors of biotechnology and information technology, and that's where the best stock pickers at Marketocracy did most of their buying last week. Within tech, however, they favored software over hardware, a group within which they sold substantial positions to lock in profits.
Lock in yields of 12% and higher on Canadian energy royalty trusts. Click here for the top picks from Forbes/Lehmann Income Security Investor.
Three of the more significant new positions the M100 took last week were in biotech, where they bought genome mapping company Human Genome Sciences (nasdaq: HGSI - news - people ),drug developer Biogen Idec (nasdaq: BIIB - news - people ) and vaccine developer ID Biomedical (nasdaq: IDBE - news - people ).
http://www.arizonabiotech.com/
Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
Biotech News
http://www.arizonaentrepreneurs.com/
Arizona Entrepreneurs
http://www.azhttp.com/
Arizona High Tech
Biotechnology News Forums
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
[ biotech news ] Alnylam Grants MWG Biotech License to Fundamental RNAi Patents for Applications
Alnylam Grants MWG Biotech License to Fundamental RNAi Patents for
Applications in the Research Products Market
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News), a leading RNAi
therapeutics company, announced today that it has granted MWG
Biotech AG, an established provider of synthetic nucleic acids, a
non-exclusive license to provide research products and services in
RNA interference (RNAi) under the Kreutzer-Limmer patent family
owned by Alnylam. This patent family covers short interfering RNAs
(siRNAs) and their use to mediate RNAi in mammalian cells.
"This agreement with MWG, an international genomic solution
provider, continues to highlight the value of the Alnylam-owned
Kreutzer-Limmer patent family as a critical component of fundamental
intellectual property in the field of RNAi," said Vincent Miles,
Ph.D., Senior Vice President, Business Development of Alnylam
Pharmaceuticals. "By leveraging our portfolio of leading IP, we are
creating value today and for the future by amassing an increasing
number of license agreements with leading reagent and service
providers. To date, fourteen companies have taken licenses for
therapeutic or research product applications, including eight
research product suppliers."
"This license strengthens our siRNA offering and is part of our
commitment to build a high quality presence in siRNA design and
production," said Dr. Wolfgang Pieken, CEO of MWG Biotech AG.
About RNA Interference (RNAi)
RNA interference, or RNAi, is a naturally occurring mechanism within
cells for selectively silencing and regulating specific genes. Since
many diseases are caused by the inappropriate activity of specific
genes, the ability to silence and regulate such genes selectively
through RNAi could provide a means to treat a wide range of human
diseases. The discovery of RNAi has been heralded by many as a major
breakthrough, and the journal Science named RNAi the top scientific
achievement of 2002, as well as one of the top 10 scientific
advances of 2003.
About Alnylam
Alnylam is a biopharmaceutical company seeking to develop and
commercialize novel therapeutics based on RNA interference, or RNAi.
Growing from its foundation as the world's first company focused on
RNAi therapeutics, the company's leadership in the field of RNAi is
supported by its preeminent founders and advisors and its strengths
in fundamental patents, technology, and know-how that underlie the
commercialization of RNAi therapeutics. Alnylam is developing a
pipeline of RNAi products using Direct RNAi(TM) to treat ocular,
central nervous system, and respiratory diseases and Systemic RNAi
(TM) to treat a broad range of diseases, including oncology,
metabolic, and autoimmune diseases. The company's global
headquarters are in Cambridge, Massachusetts. For additional
information, please visit www.alnylam.com.
About MWG Biotech AG
MWG Biotech AG (www.mwg-biotech.com) is an international provider of
DNA sequencing and DNA/siRNA synthesis products and services for
academic and industrial research from production sites in Germany,
the US, and India. With strong customer orientation, fast service
and high quality products the company creates the platform for
success in the life sciences today and for a better life tomorrow.
In its siRNA portfolio the company offers, in addition to a range of
siRNA products, a series of advance siRNA design tools and other
siRNA services.
Alnylam Forward-Looking Statements
Various statements in this release concerning our future
expectations, plans, prospects and future operating results
constitute forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform Act
of 1995. Actual results may differ materially from those indicated
by these forward-looking statements as a result of various important
factors, including risks related to: our approach to discover and
develop novel drugs, which is unproven and may never lead to
marketable products; our ability to obtain additional funding to
support our business activities; our dependence on third parties for
development, manufacture, marketing, sales and distribution of our
products; the successful development of products, all of which are
in early stages of development; obtaining regulatory approval for
products; competition from others using technology similar to ours
and others developing products for similar uses; obtaining,
maintaining and protecting intellectual property utilized by our
products; and our short operating history; as well as those risks
more fully discussed in the "Certain Factors That May Affect Future
Results" section of our most recent Form 10-Q filed with the
Securities and Exchange Commission. In addition, any forward-looking
statements represent our views only as of today and should not be
relied upon as representing our views as of any subsequent date. We
do not assume any obligation to update any forward-looking statements
http://www.arizonabiotech.com/
Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
Biotech News
http://www.arizonaentrepreneurs.com/
Arizona Entrepreneurs
http://www.azhttp.com/
Arizona High Tech
Biotechnology News Forums
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
[ biotech news ] The Sixth European Biotechnology Symposium November 13 - 15 2005
The Sixth European Biotechnology Symposium November 13 - 15 2005;
Competitive Biotechnology: Advanced Biologics Manufacturing and
Closing the Deal: Joint Ventures and Partnership
NEW ROCHELLE, N.Y. July 22, 2005--Sponsored by GENETIC ENGINEERING
NEWS and organized by BioConferences International, Inc., The Sixth
European Biotechnology Symposium at the Radisson SAS Scandinavia
Hotel in Copenhagen is the only event in Europe that assembles the
broadest collection of technical and business expertise from
Europe's rapidly-growing biomanufacturing sector.
GEN and BioConferences International will welcome all sponsors,
exhibitors and attendees at an opening reception in the expo hall on
the evening of Sunday, November 13, at the Radisson SAS Scandinavia
Hotel, Copenhagen.
The Symposium, which begins Monday, November 14, uniquely addresses
biotech's two principal concerns, technology and business, through
two consecutive tracks. "Competitive Biotechnology: Advanced
Biologics Manufacturing" (morning and afternoon, November 14 and
morning of November 15) features leading European experts in
biomanufacturing. Speakers include Dr. Prof. Florian Wurm (Swiss
Federal Institute of Technology, Lausanne) and representatives from
top biotechnology companies across Europe. "Closing the Deal: Joint
Ventures and Partnerships" (afternoon of Tuesday, November 15) will
provide a forum for business and finance experts to share their
expertise on partnership and funding activities which are critical
both to companies and the greater biotechnology industry.
Sponsors for the Sixth European Biotechnology Symposium include Host
Sponsor: Invest in Denmark, Chairs Cup: Pall Life Sciences,
Platinum: Sartorius, Diamond: Novozymes, Gold, Hyclone and Silver,
Stedim, CMC, and Linde. Additional sponsorships are available, as
well as a few non-commercial speaking opportunities.
Held approximately every other year, the European Biotechnology
Symposium has become a favorite stop on the European meeting and
conference circuit. This year's event promises even greater value
with the addition of "Closing the Deal". "This Symposium has been
extremely successful because speakers and attendees alike value the
intimate atmosphere and informative, non-commercial presentations,"
said Mary Ann Liebert, Publisher of Genetic Engineering News. "With
the addition of the 'Doing the Deal' session GEN and our partners
and sponsors hope to create a truly unique conference with broad
appeal to biotechnology scientists, engineers, and business
professionals."
For sponsorship information contact: HMatysko @ bioconferences.com
Harriet I. Matysko 914-740-2182.
registration: 914-740-2181 or 1 800 524 6266 Register on-line at
www.bioconferences.com/ebs.
BioConferences International Inc., New Rochelle
Biotech
Biotech News
Science Fairs
Entrepreneurs
High Tech
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
[ biotech news ] Ag Biotech News Being Presented at AFBF Conference
Ag Biotech News Being Presented at AFBF Conference
http://www.fb.org/news/nr/nr2005/nr0629a.html
WASHINGTON D.C., June 29, 2005 The AFBF Biotechnology Conference
will be held July 29 at the Indiana Farm Bureau headquarters in
Indianapolis.
"The conference is appropriate for anyone with an interest in the
current biotechnology situation in the United States and around the
world, as well as the outlook for agricultural biotechnology," says
Mark Maslyn, AFBF executive director of public policy.
There is no registrations fee for this national conference, but
those wishing to attend should email Donna Jackson at donnaj@fb.org
or call (202) 406-3679. For hotel accommodations the suggested hotel
nearby to contact is the Hampton Inn at telephone number 317-261-
1200.
Scheduled speakers include Cindy Smith, deputy administrator for
Biotechnology Regulatory Services under the Animal and Plant Health
Inspection Service of the Agriculture Department; Bobby Richey,
deputy director of the Foreign Agriculture Services Biotech Group at
USDA; Paul Green, international trade consultant; Barb Glenn,
director of animal biotechnology with the Biotechnology Industry
Organization; Michael Dykes, vice president, government affairs at
Monsanto; Jeff Stein, director of regulatory affairs at Syngenta
Seeds; and Mark Janis, professor of law at the University of Iowa
College of Law.
"First-hand, I know that our speakers have a great amount of
knowledge and information that they will share to enlighten
attendees," said Michelle Gorman, AFBF regulatory relations director
for biotechnology.
In general, topics being covered during the conference include
government regulations, non-food and feed uses for agricultural
biotechnology, animal biotechnology, ag biotechnology and trade,
technology fees and products in the pipeline.
Maslyn said, "Having the conference centrally located in the country
should make attendance easy and affordable for more of our members.
Additionally, the Indiana Farm Bureau office is an excellent meeting
facility."
Biotech
Biotech News
Science Fairs
Entrepreneurs
High Tech
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Science Fairs Information - Arizona Science Fairs. Science Fair Projects. Projects ideas and experiments - CARSEF - ISEF - NARSEF - AAISEF
Science Fairs Information - Arizona Science Fairs. Science Fair Projects. Projects ideas and experiments - CARSEF - ISEF - NARSEF - AAISEF
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
[ biotech news ] Trinity Biotech Completes Acquisition of Primus Corporation
Trinity Biotech Completes Acquisition of Primus Corporation
DUBLIN, IRELAND --
07/21/2005 -- Trinity Biotech plc (NASDAQ: TRIB) (ISE: TRIB.I), a
leading developer and manufacturer of diagnostic products for the
point-of-care and clinical laboratory markets, today announced that
it has completed the acquisition of Primus Corporation, a leader in
the field of in vitro diagnostic testing for haemoglobin A1c and
haemoglobin variants.
Trinity Biotech has acquired Primus for US$12 million, consisting of
a cash consideration of US$9 million and a one-year promissory note
of US$3 million. The shareholders of Primus will also be entitled to
an additional consideration of up to US$4.6 million depending on the
growth of the business during the remainder of 2005. The transaction
is being funded entirely with bank borrowings, thereby leaving
Trinity's cash balances available for future potential acquisitions.
Primus, a Kansas City, Missouri based corporation advised by
Crosstree Capital Partners, was founded in 1989 and employs 36
people in the manufacture of glycohaemoglobin instruments and
reagents to serve customers from physicians' offices to the largest
reference laboratories worldwide. Trinity is committed to further
developing the business from the Kansas City location.
Primus has demonstrated consistent sales and profit growth. Sales
increased from $3.6 million for the year 2001 to $7.9 million for
the year 2004, a compound annual growth rate of 30%. The acquisition
will be earnings positive for Trinity Biotech in 2005. As part of
the transaction, Primus CEO and founder, Tom Reidy, will remain with
the Company and continue to direct the operations of Primus within
the Trinity Group.
Ronan O'Caoimh, Trinity Biotech CEO, commented, "We are delighted to
acquire Primus which has a strong track record of growth and a
unique patented technology in the field of A1c testing. In
particular, Primus has a strong position in the US market for
variant A1c testing with an estimated market share of 35%. Trinity's
distribution network through direct sales and worldwide distributors
can further expand the Primus sales effort and ultimately result in
a significant increase in the number of instruments placed above the
current level of approximately three hundred. We are also excited
about the new Primus Rapid Gel product which is currently awaiting
FDA approval which we expect will be granted in early 2006. The
Rapid Gel product will compete in the US$100 million point-of-care
A1c market and is based on the Company's unique boronate affinity
methodology. We are confident that Primus will make a significant
contribution to Trinity's growth in future years."
Tom Reidy, CEO and founder of Primus, commented, "The acquisition of
Primus by Trinity will provide the company with access to the wider
distribution base and technical support infrastructure of Trinity's
direct sales operations in the USA, Germany and the UK and to its
worldwide distributor network. We are very excited at the
opportunities this will present to continue the growth profile of
our business and to better serve our customers."
Trinity will provide additional information regarding the
acquisition during its second quarter earnings conference call on
Thursday 28th July at 11.00am EST.
Trinity Biotech develops, acquires, manufactures and markets over
500 diagnostic products for the point-of-care and clinical
laboratory segments of the diagnostic market. The broad line of test
kits are used to detect infectious diseases, sexually transmitted
diseases, blood coagulation disorders, and autoimmune diseases.
Trinity Biotech sells worldwide in over 80 countries through its own
salesforce and a network of international distributors and strategic
partners. For further information please see the company's website:
www.trinitybiotech.com.
Forward-looking statements in this release are made pursuant to
the "safe harbor" provision of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned that such forward-
looking statements involve risks and uncertainties including, but
not limited to, the results of research and development efforts, the
effect of regulation by the United States Food and Drug
Administration and other agencies, the impact of competitive
products, product development commercialisation and technological
difficulties, and other risks detailed in the Company's periodic
reports filed with the Securities and Exchange Commission.
---------------------------------------------------------------------
-----------
SOURCE: Trinity Biotech
Arizona Biotechnology
Biotechnology News
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
[ biotech news ] Rubicon Genomics Signs Agreement with the Genome Institute of Singapore for Retr
Rubicon Genomics Signs Agreement with the Genome Institute of
Singapore for Retrospective Studies of Serum
Serum Archive Converted to Valuable Genetic Resource to Fight
Hepatitis B
ANN ARBOR, Mich., July 21
Rubicon Genomics, Inc. today announced an agreement with the Genome
Institute of Singapore to use Rubicon molecular diagnostics
technology to recover genetic information from clinical serum
samples for a large study of the immune response to vaccination
against the hepatitis B virus.
The Genome Institute of Singapore (GIS) has chosen Rubicon to
isolate and amplify very small amounts of genomic DNA in archived
serum samples from 5,000 participants in a hepatitis B vaccine
trial. Later this year, GIS will use the amplified DNA in an
international study with colleagues in Indonesia and the Netherlands
to discover genes important for hepatitis B prevention and treatment.
"These DNA isolation and amplification methods were originally
developed for sensitive non-invasive screening for cancer from
patient serum and other fluids," said Dr. John Langmore, Vice
President of Commercial Development, Rubicon Genomics. "The
enthusiasm of our diagnostic partners has been noticed by
pharmaceutical companies and institutions, who want the same
sensitive, accurate, and repeatable results for clinical trials,
pharmacogenomics, drug discovery and epidemiology."
Modern genetic research and diagnostic tests require large amounts
of DNA from millions of cells; however, the most common clinical
samples such as serum and urine rarely contain these amounts of DNA.
The proprietary Rubicon technology efficiently isolates and
amplifies DNA from 10 - 100 cells -- making faithful copies
equivalent to millions of cells.
Rubicon is developing diagnostic tests capable of detecting the
presence of fewer than 10 cancer cells in less than three hours
using DNA or methylated DNA tumor markers. Amplified DNA from one
half milliliter of serum is sufficient for unlimited genetic or
epigenetic research assays. Rubicon uses these same technologies to
discover novel biomarkers, including DNA methylation markers that it
will use in more sensitive, specific and inexpensive tests for
cancer.
About Rubicon Genomics, Inc.
Rubicon, located in Ann Arbor, Mich., USA, develops and
commercializes proprietary OmniPlex(TM) technology for molecular
diagnostics and research. In projects with commercial partners,
Rubicon discovers novel methylation markers using microarrays and
uses them to develop more sensitive and specific non-invasive
diagnostic and prognostic tests for cancer from serum, urine and
biopsies. Rubicon also has large-scale contracts to amplify and
analyze DNA and RNA from sera and biopsies for pharmaceutical
companies, academic institutions, and tissue repositories. More
information can be found at http://www.rubicongenomics.com.
The Genome Institute of Singapore
The Genome Institute of Singapore (GIS) is a member of the Agency
for Science, Technology and Research (A*STAR). Established in 2001,
the research institute's mission is to be a world-class genomics
institute and a centre for genomic discovery. GIS pursues the
integration of technology, genetics, and biology towards the goal of
individualized medicine. The genomics infrastructure at GIS is
utilized to train new scientific talent, to act as a bridge between
academic and industrial research and explore scientific questions of
high impact. More information can be found at http://www.gis.a-
star.edu.sg and http://www.a-star.edu.sg.
Arizona Biotech
Biotech News
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
C&EN: Latest News - Roche Makes Biotech Buy
C&EN: Latest News - Roche Makes Biotech Buy
Roche Makes Biotech Buy
Deal for Swiss firm GlycArt nets antibody technology
PATRICIA SHORT
Roche has agreed to acquire GlycArt Biotechnology from a syndicate of private equity investors for approximately $180 million. GlycArt, a Swiss company with technology to enhance therapeutic antibodies for the treatment of cancer and autoimmune diseases, was founded in 2000 as a spin-off from the Swiss Federal Institute of Technology (ETH) in Zurich.
GlycArt and Roche have collaborated since September 2004 using GlycArt’s GlycoMAb technology, which increases the biological activity of therapeutic monoclonal antibodies for killing specific target cells implicated in disease. The technology works by engineering the carbohydrate components of the antibodies.
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
[ biotech news ] Biotechnology, Bioinformatics, Health Informatics and Health IT Jobs
Biotechnology, Bioinformatics, Health Informatics and Health IT Jobs
Biohealthmatics.com provides career resources and services for health informatics and biotechnology professionals and employers.
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
[ biotech news ] Arizona Biotech is now listed in Science > Biology > Biotechnology
Arizona Biotech is now listed in Science > Biology > Biotechnology in the Yahoo Directory
Arizona Biotech is now listed in Science > Biology > Biotechnology in the Yahoo! Directory
Arizona Biotech Yahoo! Directory - New Additions in Science for Thursday Jun 9, 2005
Directory > Science Directory > Biology > Biotechnology
Arizona Biotech -
includes news and information on Arizona Biotechnology, genomics,
biotech companies, genetic engineering, biotech research, and biology.
Arizona Biotech
http://www.arizonabiotech.com/
Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
Biotech News
http://www.arizonaentrepreneurs.com/
Arizona Entrepreneurs
http://www.azhttp.com/
Arizona High Tech
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
BioTech Medics Announces Sales of NeuroLase Medical Device and Grand Opening of Wellness Centers
BioTech Medics Announces Sales of NeuroLase Medical Device and Grand Opening of Wellness Centers
Thursday July 14, 9:30 am ET
DALLAS, July 14 /PRNewswire-FirstCall/ -- Keith Houser, CEO of BioTech Medics, Inc., (OTC Pink Sheets: BTMD - News) announced today the sale and delivery of the NeuroLase(TM) Therapeutic Medical Laser to the Laser Pain Center, LLC, in Boca Raton, Florida.
ADVERTISEMENT
The NeuroLase is one of the most powerful Class 3 B Medical Lasers cleared for the temporary reduction of muscle, skeletal or arthritic pain over the entire body.
Additionally, the Neurolase has been sold to a medical center in the Woodland - Sacramento, California area and should be opening by August 1.
Scripts Hospital in San Diego will be using the NeuroLase starting in August. Check the BioTech Medics web site for specific addresses and details.
A demonstration of the NeuroLase has been made to staff at Mount Sinai Hospital in South Miami Beach, Florida. A decision is expected soon.
"We are getting more calls from doctors around the USA desiring information about the NeuroLase. Patients who have benefited from being treated for pain relief with the NeuroLase are getting the word out as to the safe, drug-free and surgery-free therapy", said Mr. Houser. "With our ability to offer 95% financing, the decision for a medical practitioner to acquire the laser becomes easier."
For More Information Contact BioTech Medics at 972-274-5533 or on the Internet at: http://www.biotechmedics.com .
Safe Harbor for Forward-Looking Statements
This press contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). In Particular, when used in the preceding discussion, the words "plan," "confident that," "believe," "scheduled," "expect," or "intend to," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, the ability of the company to have adequate financing, market conditions, the general acceptance of the Company's products and technologies, competitive factors, timing, and other risks described in various Company publications.
CONTACT: BioTech Medics, Inc., +1-972-274-5533
Web site: http://www.biotechmedics.com
--------------------------------------------------------------------------------
Source: BioTech Medics, Inc.
Marketing Firms - Search Engine Marketing Firms
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotech firms fight pollution with plants
Globetechnology: Biotech firms fight pollution with plants
Biotech firms fight pollution with plants By PAUL ELIAS
Friday, July 15, 2005 Updated at 3:47 PM EDT
Associated Press
On the site of a former hat factory in Danbury, Conn., a stand of genetically altered cottonwood trees sucks mercury from the contaminated soil.
Across the continent in California, researchers use transgenic Indian mustard plants to soak up dangerously high selenium deposits caused by irrigation of the nation's bread basket.
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Trypanosome genomes - Deadly Parasites Have Common Genetic Core - THE INSTITUTE FOR GENOMIC RESEARCH
Trypanosome genomes - Deadly Parasites Have Common Genetic Core
THE INSTITUTE FOR GENOMIC RESEARCH
Deadly Parasites Have Common Genetic Core;
Studies May Help Target New Drugs to Fight Them
Scientists decipher, compare the genomes of parasites that threaten
half a billion people, causing Chagas disease, Sleeping Sickness and
Leishmaniasis
One parasite causes a deadly sleeping sickness in Africa. The second
damages the internal organs of millions of Latin Americans. The
third causes terrible lesions on the face or limbs of victims from
Brazil to India.
The three parasites the culprits behind African sleeping sickness,
Chagas disease and leishmaniasis cause markedly varying diseases
and are carried by different insect vectors. But scientists have
found that the pathogens have a core of about 6,200 conserved genes.
Their genetic similarities far outweigh their differences.
"This common core of genes is extremely important because it may
provide targets for a new generation of drugs that might fight all
three parasites, which threaten millions of people worldwide," says
Najib El-Sayed, the first author of two of the parasite papers that
appear in the July 15 issue of Science and senior author of a third
paper. "At the moment, there are no vaccines and only a few
inadequate drugs to fight these devastating and neglected diseases."
El-Sayed is a molecular biologist at The Institute for Genomic
Research (TIGR), of Rockville, Maryland, which conducted the genome
sequencing and analysis along with scientists at the Wellcome Trust
Sanger Institute in Hinxton, U.K.; the Seattle Biomedical Research
Institute (SBRI); and the Karolinska Institutet, in Stockholm,
Sweden.
The Science issue includes several related papers, including genome
studies of Trypanosoma cruzi, which causes Chagas disease;
Trypanosoma brucei, which causes African trypanosomiasis, also known
as sleeping sickness; and Leishmania major, which causes the skin
disease leishmaniasis and an internal disease known as kala azar.
Another paper compares the three related genomes.
By determining the shared genes and focusing on those that differ,
the comparative study sheds important new light on the genetic basis
for the differences between the parasites including how they
infect people, how they cause human disease, and why they are
carried by different insects. (T. cruzi is carried by blood-sucking
triatomine insects; T. brucei by the tsetse flies; and L. major by
sand flies.)
The comparison found dozens of genes found in all three parasites
that may have been acquired from bacteria through lateral gene
transfer. In addition, studies of the parasites' Variant Surface
Glycoproteins (VSGs) found T. brucei to have the most complex
genetic apparatus for avoiding host immune systems and, at the same
time, to be the most dependent of the parasites on the host's
metabolism. Scientists also discovered that many of the genes
specific to each species are found in so-called sub-telomeric
regions near the ends of chromosomes areas where the genome tends
to be more changeable.
An important finding in the T. cruzi genome study was the discovery
of a novel and large set of 1,300 genes (called the "mucin-
associated surface protein," or MASP, genes) that may play a role in
the parasite's evasion of the human immune system or in its ability
to survive in the variety of hosts that it infects.
The T. cruzi project was funded by the National Institute of Allergy
and Infectious Diseases (NIAID), part of the U.S. National
Institutes of Health. The major funders of the T. brucei and L.
major genome projects were The Wellcome Trust and the NIAID.
Matthew Berriman of Sanger, the first author of the T. brucei genome
paper, predicts that the genome sequences will help advance research
into diseases that have been "neglected" in the past. "Genome
sequences allow ideas to be tested and more quickly turned into
reality," Berriman says. "The basic building blocks of all three
parasites are now known."
Peter J. Myler of SBRI, who shared the first authorship with El-
Sayed on two of the papers, says: "Now that the genes of these
parasites are mapped out, it's much easier to identify genes that
are critical for parasite survival. Genes encoding proteins that are
involved in critical biological processes often serve as drug
targets."
Much of the world's population in tropical and sub-tropical areas is
at risk of contracting one or more of the diseases. Chagas disease
which may have infected Charles Darwin infects as many as 18
million people and threatens about 100 million others in Latin
America, according to the World Health Organization. African
sleeping sickness (trypanosomiasis) infects between 300,000 and
500,000 persons and threatens more than 60 million people in 36
countries in sub-Saharan Africa. Leishmaniasis (which also can be
caused
by related parasites) is endemic in 88 countries and may threaten
as many as 300 million people.
*
* *
The Institute for Genomic Research (TIGR), which sequenced the first
complete genome of a free-living organism in 1995, is a not-for-
profit research institute based in Rockville, Maryland. TIGR
conducts research involving the structural, functional, and
comparative analysis of genomes and gene products in viruses,
bacteria, archaea, and eukaryotes.
[In addition to his faculty position at TIGR, Dr. El-Sayed also
holds an appointment in the microbiology and tropical medicine
department at the George Washington University School of Medicine in
Washington, D.C.]
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
[ biotech news ] Re: hello everyone
--- In biotech-news@yahoogroups.com, "samreen_btech"
<samreen_btech@y...> wrote:
> hello
>
> iam samreen doin my engg frm in biotechnology
>
> i just wanna know the top 100 universities offering biotech course
for
> ms in usa
>
> bubye
Here are a couple of places to start looking:
Arizona Biodesign Institute at Arizona State University
http://www.biodesign.org/
and the Institute for Biomedical Science and Biotechnology at
University of Arizona.
http://bio5.org/
Bill Austin
http://www.arizonabiotech.com/
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
[ biotech news ] hello everyone
hello
iam samreen doin my engg frm in biotechnology
i just wanna know the top 100 universities offering biotech course for
ms in usa
bubye
Arizona High Tech
Biotechnology Forums
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Sonus Pharmaceuticals Sublicenses Non-Core Oxygen Delivery Patents to ImaRx Therapeutics
Sonus Pharmaceuticals Sublicenses Non-Core Oxygen Delivery Patents to ImaRx Therapeutics
Sonus Pharmaceuticals, Inc. (Nasdaq:SNUS) today announced that it has sublicensed intellectual property for fluorocarbon-based oxygen delivery applications to ImaRx Therapeutics, Inc. This oxygen delivery technology is not part of Sonus' core research, which shifted several years ago to the development of novel cancer drug therapies utilizing a vitamin E-based technology.
Under the sublicensing agreement, ImaRx will obtain exclusive rights to four patents covering Sonus' fluorocarbon technology, including both composition of matter patents and patents directed to methods of using the technology to deliver oxygen for therapeutic applications. Upon commercialization of any resulting products, ImaRx will pay a royalty to Sonus.
"We are pleased that we now have an opportunity to monetize our past investment in fluorocarbon technology, which had been an earlier business focus of Sonus. We are currently developing drugs for the treatment of cancer based on our TOCOSOL(R) vitamin E technology platform and are no longer pursuing the application of the fluorocarbon technology. However, we believe this technology is unique among approaches to oxygen delivery and has value for a company like ImaRx exploring a variety of potential applications in this field," said Michael A. Martino, President and CEO of Sonus Pharmaceuticals.
About Sonus Pharmaceuticals, Inc.
Headquartered near Seattle, Washington, Sonus Pharmaceuticals, Inc. is focused on the development of therapeutic drugs that may offer improved administration, safety, tolerability and effectiveness for the treatment of cancer and related conditions. The Company's lead product candidate is TOCOSOL Paclitaxel, a novel formulation of the widely prescribed anti-cancer drug paclitaxel. TOCOSOL Paclitaxel has been designed to overcome the limitations associated with Taxol(R) and generic paclitaxel-based chemotherapy, including long infusion times, undesirable or treatment-limiting side effects as well as time consuming and expensive preparation of the products prior to administration. The U.S. Food and Drug Administration has completed a Special Protocol Assessment (SPA) for the pivotal Phase 3 trial of TOCOSOL Paclitaxel, which Sonus expects to initiate in 2005. For additional information about the Company, including news releases, please visit www.sonuspharma.com.
About ImaRx Therapeutics, Inc.
ImaRx, a privately held biopharmaceutical company, develops NanoInvasive(TM) therapies for the treatment of cardiovascular and CNS diseases, and cancers. The company's lead product, SonoLysis(TM), combines the power of ultrasound with proprietary nanobubbles to locally dissolve blood clots without the use of invasive surgery or potentially dangerous lytic drugs. SonoLysis is currently in a Phase II study for stroke and a Phase I/II study for peripheral arterial occlusive disease. For more information, please visit www.imarx.com.
Safe Harbor
Certain statements made in this press release are forward-looking such as those, among others, relating to the development, safety and efficacy of drug delivery products and potential applications for these products or the anticipated date of the initiation of Phase 3 clinical trials for TOCOSOL Paclitaxel. As discussed in Sonus Pharmaceuticals' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K filed on March 23, 2005, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: the company's products will require extensive clinical testing and approval by regulatory authorities; such approvals are lengthy and expensive and may never occur; risks that the company will not be able to initiate Phase 3 clinical trials for TOCOSOL Paclitaxel; risks that clinical studies with TOCOSOL Paclitaxel will not be successful; risks that the FDA may not approve the company's proposed New Drug Application; risks of successful development of additional drug delivery products; and risks that the company may not be successful in obtaining funding from third parties or completing a financing necessary to support the costs and expenses of clinical studies as well as research and development activities. The company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.
Taxol(R) is a registered trademark of Bristol-Myers Squibb Company.